Table 4.
Disease categories
|
Study object/model
|
Effect induced by autophagy
|
Mechanism (targets or pathways)
|
Ref.
|
Diabetic peripheral neuropathy | A high-glucose medium in Schwann cells | Antioxidant activity via (-) the autophagy overactivation of Schwann cells | (-) Reactive oxygen species and (-) autophagy-related proteins (LC3, PINK and Parkin); protective effect (mitochondrial morphology and membrane potential) | Wei et al[38] |
Diabetic peripheral neuropathy | High-fat diet in rats; high glucose in Schwann RSC96 cells | (-) The myelin sheath injury by the apoptosis of Schwann cells via (+) autophagy | (-) The activation of the PI3K/Akt/mTOR signalling pathway by (+) miR-155 expression | Yin et al[41] |
DN | KK-Ay diabetic mice; immortalized mouse podocytes | (-) Glucose-induced podocyte EMT and (+) enhanced autophagy | The SIRT1–NF-κB pathway | Wang et al[40] |
DN | STZ diabetic mice; high glucose in podocytes | (-) The progression of DN via (+) autophagy induction | AMPKα-promoted autophagy induction | Guo et al[39] |
Liver injury in diabetics | Highfat diets + lowdose STZ in diabetic liver injury rats | (+) Autophagy in the liver of T2DM rats; (-) IR, dyslipidaemia, oxidative stress and inflammation | The promotion of AMPK/mTORmediated autophagy | Zhu et al[42] |
LC: Lung cancer; PINK: PTEN-induced putative kinase 1; RSC: Rat Schwann cells; KK-Ay: Spontaneous diabetes; EMT: Epithelial-mesenchymal transition; STZ: Streptozotocin; DN: Diabetic nephropathy; IR: Immunoreactive; T2DM: Type 2 diabetes mellitus.